본문 바로가기
KERD
논문KCI 등재

일 정신병원에 입원한 조현병 환자의 대사지표와 관련된 비정형 항정신병약물 요인

A Study on Factors Associated with Abnormal Metabolic Parameters Among Inpatients with Schizophrenia Taking Atypical Antipsychotics : A Cross Sectional Study

이준영|박종익|김지완|견영기
대한생물치료정신의학회 (Korean Society Of Biological Therapies In Psychiatry)|2017.06|생물치료정신의학 (Journal of the Korean Society of Biological Therapies in Psychiatry)|제23권 제2호|pp. 84-94|DOI 10.22802/jksbtp.2017.23.2.84

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

중심 단어：조현병·비정형 항정신병 약물·대사 관련 지표·BMI.KEY WORDS：Schizophrenia · Atypical antipsychotic agents · Metabolic parameters · Body mass index.
주제분류정신과학

초록

Objectives：Patients with schizophrenia have been reported to be more vulnerable to metabolic diseases than the general population. This study aimed to assess the prevalence of abnormal metabolic parameters and identify the factors of atypical antipsychotic drugs associated with these abnormalities in patients with schizophrenia taking atypical antipsychotic drugs. Methods：A total of 161 inpatients with schizophrenia were recruited at Chuncheon National Hospital for 1 year in 2015. We collected demographic information, medication history, physical measurements, and metabolic parameters(body mass index(BMI), systolic and diastolic blood pressures, and serum total cholesterol and serum triglyceride levels) from the medical records of the patients. We categorized the patients into an abnormal metabolic parameters group and a control group and performed comparative analysis between the groups. Results：Among the 161 inpatients, 56.5% were overweight(BMI≥25kg/m2) and 42.2% had hypertension. The prevalence of hypercholesterolemia(total cholesterol level＞200mg/dL) and hypertriglyceridemia(triglyceride level ＞150mg/dL) was 23.6% and 43.5%, respectively. Being overweight was strongly associated with higher total daily chlorpromazine-equivalent dose but not with age, sex, or antipsychotic polypharmacy. Conclusion：Metabolic abnormalities are highly prevalent among patients with chronic schizophrenia. These results suggest that higher chlorpromazine-equivalent doses are associated with greater weight gain. Clinicians should be aware of the risk of metabolic abnormalities associated with a chlorpromazine-equivalent doses of antipsychotic drugs.

Abstract

Objectives：Patients with schizophrenia have been reported to be more vulnerable to metabolic diseases than the general population. This study aimed to assess the prevalence of abnormal metabolic parameters and identify the factors of atypical antipsychotic drugs associated with these abnormalities in patients with schizophrenia taking atypical antipsychotic drugs. Methods：A total of 161 inpatients with schizophrenia were recruited at Chuncheon National Hospital for 1 year in 2015. We collected demographic information, medication history, physical measurements, and metabolic parameters(body mass index(BMI), systolic and diastolic blood pressures, and serum total cholesterol and serum triglyceride levels) from the medical records of the patients. We categorized the patients into an abnormal metabolic parameters group and a control group and performed comparative analysis between the groups. Results：Among the 161 inpatients, 56.5% were overweight(BMI≥25kg/m2) and 42.2% had hypertension. The prevalence of hypercholesterolemia(total cholesterol level＞200mg/dL) and hypertriglyceridemia(triglyceride level ＞150mg/dL) was 23.6% and 43.5%, respectively. Being overweight was strongly associated with higher total daily chlorpromazine-equivalent dose but not with age, sex, or antipsychotic polypharmacy. Conclusion：Metabolic abnormalities are highly prevalent among patients with chronic schizophrenia. These results suggest that higher chlorpromazine-equivalent doses are associated with greater weight gain. Clinicians should be aware of the risk of metabolic abnormalities associated with a chlorpromazine-equivalent doses of antipsychotic drugs.

참고문헌 (49)

  1. Olfson M, "Premature mortality among adults with schizophrenia in the U.S", JAMA Psychiatry, 72, pp.1172~1181 (2015)
  2. Expert Panel on Detection E, Treatment of High Blood Cholesterol in Adults, "Executive summary of the third report of The national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults(Adult Treatment Panel III)", JAMA, 285, pp.2486~2497 (2001)
  3. McEvoy JP, "Prevalence of the metabolic syndrome in patients with schizophrenia:baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness(CATIE) schizophrenia trial and comparison with national estimates from NHANES III", Schizophr Res, 80, pp.19~32 (2005)
  4. Beltrán-Sánchez H, "Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010", J Am Coll Cardiol, 62, pp.697~703 (2013)
  5. Hägg S, "High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia", Int Clin Psychopharmacol, 21, pp.93~98 (2006)
  6. Cohn T, "Characterizing coronary heart disease risk in chronic schizophrenia:high prevalence of the metabolic syndrome", Can J Psychiatry, 49, pp.753~760 (2004)
  7. Wirshing DA, "Schizophrenia and obesity: impact of antipsychotic medications", J Clin Psychiatry, 65(Suppl 18), pp.13~26 (2004)
  8. Newcomer JW, "Antipsychotic medications:metabolic and cardiovascular risk", J Clin Psychiatry, 68(Suppl 4), pp.8~13 (2007)
  9. Woods SW, "Chlorpromazine equivalent doses for the newer atypical antipsychotics", J Clin Psychiatry, 64, pp.663~667 (2003)
  10. Chue P, "Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets", Eur Neuropsychopharmacol, 15, pp.111~117 (2005)
  11. Xiang YT, "Antipsychotic polypharmacy in inpatients with schizophrenia in Asia(2001-2009)", Pharmacopsychiatry, 45, pp.7~12 (2012)
  12. 최진영, "조현병 환자에서 항정신병약물 병용요법 분석 : 임상적관련인자 및 처방현황 조사", 신경정신의학, 53(6), pp.370~378 (2014), 대한신경정신의학회[DOI]
  13. Correll CU, "Antipsychotic combinations vs monotherapy in schizophrenia:a meta-analysis of randomized controlled trials", Schizophr Bull, 35, pp.443~457 (2009)
  14. Josiassen RC, "Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial", Am J Psychiatry, 162, pp.130~136 (2005)
  15. Honer WG, "Clozapine alone versus clozapine and risperidone with refractory schizophrenia", N Engl J Med, 354, pp.472~482 (2006)
  16. Joukamaa M, "Schizophrenia, neuroleptic medication and mortality", Br J Psychiatry, 188, pp.122~127 (2006)
  17. McQuillan GM, "National health and nutrition examination survey biospecimen program: NHANES III(1988-1994) and NHANES 1999-2014", Vital Health Stat, 170, pp.1~14 (2015)
  18. 2012 National health screening statistical yearbook, "Jung HJ", National Health Insurance Service, ~ (2013)
  19. 송명선, "입원 치료 중인 조현병 환자의 비만도와 정신병리", 신경정신의학, 54(2), pp.172~180 (2015), 대한신경정신의학회[DOI]
  20. Newcomer JW, "Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia", Arch Gen Psychiatry, 59, pp.337~345 (2002)
  21. Faulkner G, "Body mass index, waist circumference and quality of life in individuals with schizophrenia", Schizophr Res, 90, pp.174~178 (2007)
  22. Czobor P, "Antipsychotic-induced weight gain and therapeutic response: a differential association", J Clin Psychopharmacol, 22, pp.244~251 (2002)
  23. Lambert M, "Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence", Eur Psychiatry, 19, pp.415~422 (2004)
  24. Lawes CM, "Blood pressure and cardiovascular disease in the Asia Pacific region", J Hypertens, 21, pp.707~716 (2003)
  25. 김현창, "Noncommunicable Diseases: Current Status of Major Modifiable Risk Factors in Korea", 예방의학회지, 46(4), pp.165~172 (2013), 대한예방의학회
  26. Kim HC, "Comparison of blood pressure-associated risk of intracerebral hemorrhage and subarachnoid hemorrhage: Korea Medical Insurance Corporation study", Hypertension, 46, pp.393~397 (2005)
  27. Goff DC Jr, "2013 ACC", AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology, Circulation, pp.2014, 129[DOI]
  28. Stone NJ, "2013 ACC", AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology, Circulation, pp.2014, 129[DOI]
  29. Fleischhacker WW, "Comorbid somatic illnesses in patients with severe mental disorders:clinical, policy, and research challenges", J Clin Psychiatry, 69, pp.514~519 (2008)
  30. Fujimaki K, "Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia", PLos One, 7, pp.e37087~ (2012)
  31. Koreki A, "Clinical and demographic characteristics associated with postural instability in patients with schizophrenia", J Clin Psychopharmacol, 31, pp.16~21 (2011)
  32. Franca Centorrino, "Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics", Hum Psychopharmacol, 27, pp.521~526 (2012)
  33. Allison DB, "The distribution of body mass index among individuals with and without schizophrenia", J Clin Psychiatry, 60, pp.215~220 (1999)
  34. Homel P, "Changes in body mass index for individuals with and without schizophrenia, 1987-1996", Schizophr Res, 55, pp.277~284 (2002)
  35. 노재우, "정신분열병 입원 환자에서의 대사 증후군 유병률 연구", 생물정신의학, 18(1), pp.46~54 (2011), 대한생물정신의학회
  36. 남윤영, "만성 정신분열병 환자들의 대사증후군과 관련된 임상 특징들", 대한정신약물학회지, 17(4), pp.335~341 (2006), 대한정신약물학회
  37. Batsis JA, "Metabolic syndrome: from global epidemiology to individualized medicine", Clin Pharmacol Ther, 82, pp.509~524 (2007)
  38. Alvarez-Jiménez M, "Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: systematic critical reappraisal", CNS Drugs, 22, pp.547~562 (2008)
  39. 이화영, "조현병, 조현정동장애 외래 환자들의 대사증후군 유병률", 대한조현병학회지, 15(1), pp.39~45 (2012), 대한조현병학회
  40. 정선화, "조현병 환자에서 항정신약물이 대사지표에 미치는 영향 조사 - 1년 추적연구", 대한조현병학회지, 18(2), pp.59~65 (2015), 대한조현병학회
  41. Newcomer JW, "Second-generation(atypical) antipsychotics and metabolic effects: a comprehensive literature review", CNS Drugs, 19(Suppl1), pp.1~93 (2005)
  42. Wirshing DA, "Schizophrenia and obesity: impact of antipsychotic medications", J Clin Psychiatry, 65(Suppl 18), pp.13~26 (2004)
  43. Newcomer JW, "Antipsychotic medications: metabolic and cardiovascular risk", J Clin Psychiatry, 68(Suppl4), pp.8~13 (2007)
  44. Atmaca M, "Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics", J Clin Psychiatry, 64, pp.598~604 (2003)
  45. Pramyothin P, "Metabolic syndrome with the atypical antipsychotics", Curr Opin Endocrinol Diabetes Obes, 17, pp.460~466 (2010)
  46. De Hert MA, "Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication", Schizophr Res, 83, pp.87~93 (2006)
  47. Krane-Gartiser K, "Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics", Nord J Psychiatry, 65, pp.345~352 (2011)
  48. Bobes J, "Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort", Schizophr Res, 119, pp.101~109 (2010)
  49. Maarten Bak, "Almost all antipsychotics result in weight gain: a meta-analysis", PLoS One, 9, pp.e94112~ (2014)

관련 논문AI추천

조현병 환자에서 항정신약물이 대사지표에 미치는 영향 조사 - 1년 추적연구박은경, 윤해주, 이종일, 임선진, 정선화대한조현병학회 · 대한조현병학회지2015 · 제18권 제2호조현병 환자에서 비전형항정신병약물 사용시 대사지표에 미치는 영향 조사 : 3년 추적연구박은경, 배하현, 윤해주, 이종일대한조현병학회 · 대한조현병학회지2017 · 제20권 제1호Metabolic Disturbances Independent of Body Mass in Patients with Schizophrenia Taking Atypical Antipsychotics강시현, 이종일대한신경정신의학회 · PSYCHIATRY INVESTIGATION2015 · 제12권 제2호Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study권준수, 김대호, 김성완, 김재진, 김종훈, 남희정, 박일호, 안석균, 오홍석, 원승희, 유승형, 이강욱, 이규영, 이승환, 이유상, 이중서, 이중선, 주연호, 홍경수대한신경정신의학회 · PSYCHIATRY INVESTIGATION2017 · 제14권 제1호항정신병약물을 처음으로 사용하는 초발 정신증 환자에서 나타나는 체중 및 대사성 지표의 변화 : 후향적 연구강제욱, 공보금, 김민걸, 김성진, 김우진, 김정은, 김현정, 문정준, 박민경, 심주철, 정도운대한생물치료정신의학회 · 생물치료정신의학2011 · 제17권 제2호한국인 정신분열병 환자에서 비정형 항정신병 약물의 치료반응과 체중증가의 관련성에 대한 연구이민수, 이재병, 이화영, 함병주대한생물정신의학회 · 생물정신의학2011 · 제18권 제4호

이 간행물의 다른 논문 (2건)

조현병 환자의 내재화된 낙인과 관련된 요인김재민, 윤진상, 김선영, 이주연, 김성완, 정유란, 유태영pp. 75-83유방암 환자에서 항암화학요법 후 인지기능과 후각기능의 변화 : 예비연조수현, 고수진, 임종석pp. 95-107
원문 보기